Argyle Capital Partners’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$400K Sell
593
-127
-18% -$75.4K 0.25% 104
2026
Q2
$361K Buy
720
+83
+13% +$39.8K 0.23% 118
2026
Q1
$313K Buy
637
+111
+21% +$60.2K 0.23% 118
2025
Q4
$305K Sell
526
-139
-21% -$78.6K 0.22% 117
2025
Q3
$322K Sell
665
-140
-17% -$65.2K 0.23% 120
2025
Q2
$326K Buy
+805
New +$337K 0.27% 105

Other funds holding TMO

Argyle Capital Partners's TMO Position: Q3 2026 in Review

Argyle Capital Partners reduced its Thermo Fisher Scientific (TMO) stake by 18% in Q3 2026, selling an estimated $75.4K and leaving 593 shares worth $400K. The position accounts for 0.25% of the portfolio, ranked #104.

Argyle Capital Partners first reported a position in TMO in Q2 2025 and has held it in 6 quarters since. 2,450 funds tracked by Wall St. Rank hold TMO as of Q3 2026.

  • Argyle Capital Partners held 593 shares of Thermo Fisher Scientific worth $400K as of Q3 2026.
  • Argyle Capital Partners sold 127 Thermo Fisher Scientific shares in Q3 2026, an estimated $75.4K.
  • Thermo Fisher Scientific made up 0.25% of Argyle Capital Partners's portfolio in Q3 2026, its #104 holding.
  • Argyle Capital Partners first reported a position in Thermo Fisher Scientific in Q2 2025 and has held it in 6 quarters since.
  • 2,450 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q3 2026.

Based on Argyle Capital Partners's 13F filing for Q3 2026, filed 23 Oct 2026.